



Thor Medical - Issuance of shares to executive member under incentive program

6.1.2026 08:52:11 CET | Thor Medical ASA | Mandatory notification of trade primary insiders

6 January 2026 | Thor Medical ASA | Mandatory notification of trade primary insiders

The Board of Directors of Thor Medical ASA (the "**Company**") has decided to award Chief Technology Officer Prof. Sindre Hassfjell a cash bonus, subject to the net bonus after taxes being invested in shares in the Company.

The award is made in recognition of Prof. Hassfjell's significant contributions, to date and going forward, to the Company's intellectual property portfolio.

The Board of Directors has in connection with the bonus award issued 63,739 shares to Prof. Hassfjell. The subscription price for each share has been set to the volume-weighted average trading price (VWAP) of the Company's shares on Oslo Stock Exchange during the 10 trading days immediately preceding the date of the award, being NOK 4.95. The shares are subject to lock-up until the end of 2027. The bonus award is further subject to customary terms and conditions for employee incentive programs.

Following the issuance and delivery of the new shares, Prof. Hassfjell holds and controls 143,739 shares and 2,700,000 share options in the Company.

The Company's existing shareholder's pre-emptive rights to subscribe for shares is set aside in consideration of the purpose of the incentive program and the share capital increase.

Upon completion of the issuance of shares, the Company's share capital will be increased with a total of NOK 12,748, by issuing 63,739 new shares. After completion, the share capital of Thor Medical ASA will be NOK 70,844,127 divided on 354,220,633 shares, each with a nominal value of NOK 0.20.

Notification of the transaction in accordance with the Market Abuse Regulation Article 19 is attached to this announcement.

CONTACTS

John Andersen, Jr., Chair of the Board of Directors, +47 90 17 40 80, john.andersen@scatec.no

ABOUT THOR MEDICAL ASA

Thor Medical is an emerging supplier of radionuclides, primarily alpha particle emitters, from naturally occurring thorium. Its proprietary production process requires no irradiation or use of nuclear reactors, and provides reliable, environmentally friendly, cost-efficient supply of alpha-emitters for the radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'.

To learn more, visit www.thormedical.com - <https://www.thormedical.com>.

Attachments

- [Download announcement as PDF.pdf](#)
- [Skjema for melding om transaksjoner av personer med ledelsesansvar KRT-1500.pdf](#)